PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Study started of new SFX-01 tablet formulation

16 Nov 2022 07:00

RNS Number : 5254G
Evgen Pharma PLC
16 November 2022
 

Evgen Pharma plc

("Evgen" or the "Company")

 

 

Study to investigate performance of new SFX-01 tablet formulation

 

First healthy volunteers dosed on schedule

 

 

Alderley Park, UK - 16 November 2022: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, further to the announcement on 12 November 2022, it has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. The study aims to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of SFX-01, as well as investigating how sulforaphane released from SFX-01 engages with key molecular targets of interest.

 

The new enteric-coated tablet formulation will replace the prototype formulation, which used manually-filled capsules. It releases sulforaphane to a targeted part of the intestine, with the goals of predicable release and minimisation of gastro-intestinal side effects. The new formulation, if it performs as expected, will be suitable for large scale trials and commercial supply.

 

Dr Huw Jones, Evgen CEO, commented:

"This first dosing, on schedule, marks an important further step in our development plan for SFX-01. We believe it will confirm the improved delivery of SFX-01 through our new formulation. In addition, we will gain further insights into how the asset engages with key molecular targets of interest as Evgen expands into new indications in oncology and neurodevelopmental disorders."

 

SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The Company has already completed three trials in patients, including a positive open label trial in metastatic breast cancer using a prototype capsule formulation.

 

Evgen's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Sulforaphanes have shown potential benefits in neurodevelopmental disorders, oncology and inflammatory conditions. SFX-01, Evgen's lead asset, is the only stabilised sulforaphane suitable for clinical research and eventual approval as a medicine.

 

A pharmacokinetic study looks at how the drug is absorbed and circulates in the body, while a pharmacodynamic study investigates how the drug engages with molecular targets relevant to disease. The current healthy volunteer study examines both in a double-blinded placebo-controlled modular design.

 

-Ends-

 

Enquiries:

Evgen Pharma plcDr Huw Jones, CEO Richard Moulson, CFO 

+44 1625 466591

FinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance)Alice Lane/Nigel Birks (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon

+44 207 457 2020Evgen@Instinctif.com

 

 

Notes to Editors

 

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. 

 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has completed, with a positive outcome, a Phase 2a clinical trial for oestrogen-positive (ER+) metastatic breast cancer. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

 

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology. In addition, Evgen has a licensing deal in neurodevelopmental disorders and schizophrenia with Stalicla SA, a company specialising in the identification of specific phenotypes of autism spectrum disorder via a proprietary screening system.

 

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG. 

 

For further information, please visit: www.evgen.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RESBKPBKCBDDQDD
Date   Source Headline
17th Jun 20207:00 amRNSSFX-01 to be evaluated in COVID-19 trial
15th Jun 20205:05 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSFinal Results
8th Jun 20207:00 amRNSPaper on SFX-01 in ER positive breast cancer
5th Jun 20207:00 amRNSNotice of Results
15th May 202012:30 pmRNSStatement Re: Share Price Movement
30th Apr 20207:00 amRNSDirectorate Change
20th Feb 20209:27 amRNSHolding(s) in Company
13th Feb 20207:00 amRNSUniversity of Rochester Collaboration
6th Feb 20207:00 amRNSUniversity of Manchester collaboration discovery
29th Jan 20202:05 pmRNSSecond Price Monitoring Extn
29th Jan 20202:00 pmRNSPrice Monitoring Extension
20th Jan 20203:39 pmRNSHolding(s) in Company
17th Jan 20203:32 pmRNSHolding(s) in Company
8th Jan 20209:52 amRNSHolding(s) in Company
17th Dec 20197:01 amRNSInvestor presentation
17th Dec 20197:00 amRNSHalf-year Report
5th Dec 20197:00 amRNSMOU with The University of Dundee
4th Dec 20193:11 pmRNSNotice of Results
14th Nov 201911:59 amRNSHolding(s) in Company
11th Nov 201912:11 pmRNSSAS study clarification
11th Nov 20197:00 amRNSSFX-01 results in SAS study
30th Sep 20197:00 amRNSESMO presentation of Phase II STEM clinical data
23rd Sep 20197:00 amRNSUpdate on extended-use phase of STEM trial
5th Sep 20197:00 amRNSAgreement for supply of SFX-01 for autism trial
28th Aug 20197:00 amRNSUpdate on SAS study
7th Aug 20197:00 amRNSGrant of further European patent
5th Aug 20197:00 amRNSResearch collaboration
25th Jul 20191:00 pmRNSGrant of Options
18th Jul 20193:47 pmRNSResult of AGM
18th Jul 20197:00 amRNSAGM Statement
24th Jun 20197:00 amRNSSFX-01 featured in SAH review paper
19th Jun 201910:39 amRNSPosting of Annual Report and AGM Notice
13th Jun 20197:00 amRNSFull Year Results
11th Jun 20197:00 amRNSNotification of Preliminary Results
22nd May 20191:32 pmRNSHolding(s) in Company
21st May 20197:00 amRNSShare Option Exercise and Issue of Equity
9th May 20195:49 pmRNSHolding(s) in Company
9th May 201910:11 amRNSHolding(s) in Company
8th May 201911:29 amRNSResult of GM and Completion of Placing
26th Apr 201911:05 amRNSSecond Price Monitoring Extn
26th Apr 201911:00 amRNSPrice Monitoring Extension
24th Apr 201911:37 amRNSHolding(s) in Company
24th Apr 201911:33 amRNSHolding(s) in Company
23rd Apr 20192:05 pmRNSSecond Price Monitoring Extn
23rd Apr 20192:00 pmRNSPrice Monitoring Extension
23rd Apr 201910:30 amRNSHolding(s) in Company
18th Apr 20195:30 pmRNSPosting of Circular and Timing of General Meeting
17th Apr 20191:00 pmRNSPlacing and Notice of General Meeting
2nd Apr 20199:00 amRNSfinnCap publishes initiation research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.